US pricing watchdog spotlights an old pharma trick
Hiking the price of a drug before generics appear is a long-enshrined practice, a situation that applies to most of the products singled out by Icer.
Deal-depressed third quarter leaves nowhere to hide
Megadeals flattered the biopharma M&A scene in the first half of 2019, but the numbers took a nose dive in the third-quarter.
Europe and Asia provide a safe haven as US stocks falter
Non-US big biopharma stocks led the way in the third quarter, suggesting that those looking for investment gains would do best to search further afield.
Bristol joins the pharma buyers club
An analysis of EvaluatePharma data shows that, in a Bristol-Myers Squelgene world, all big pharmas are increasing their reliance on external projects.
Roche and Celgene set for battle in acute myelogenous leukaemia
Last week's pivotal trial success could give Celgene a second AML drug, setting up a battle against Roche's Venclexta and idasanutlin.
Six burning Otezla questions
Planned divestment of Celgene’s psoriasis blockbuster means instant cashback for Bristol, a result the markets see as a win-win-win.
Success still eludes pancreatic cancer pipeline
Nucana’s recent setback with Acelarin adds to the long list of pancreatic cancer failures, and a look at the late-stage pipeline shows little concrete progress.
Biopharma's biggest sellers – the oldies that just keep giving
Patent expiries and challenges have done little to halt the sales of some of the industry's biggest products.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.